Entrada Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $294.8M
- Price
- $7.57
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.39%
- Volume
- 141.0K
About
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
Quick stats
Shares outstanding38.9M
Computed float25.2M
Float / shares64.7%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001689375
Websitehttps://www.entradatx.com
AI Summary
AI-generated1/34
minorneutralearnings
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
Entrada Therapeutics reported Q2 2026 financial results with cash, cash equivalents, and marketable securities of $223.0 million, which management believes is sufficient to fund operations into the third quarter of 2027.
Collaboration revenue for the quarter decreased to $0.9 million from $2.0 million in the prior year, while the net loss narrowed slightly to $42.8 million driven by lower personnel and facility costs.
On the clinical front, the company completed enrollment for Cohort 2 of the ELEVATE-44-201 study and Cohort 1 of the ELEVATE-45-201 study, with data readouts anticipated between October 2026 and the first half of 2027.
Red flags
- Collaboration revenue decreased 55% year-over-year
- Cash runway extends only to Q3 2027